Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Hotspot Therapeutics Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners, which means the company is interacting with multiple reviewers simultaneously. The prosecution is also divided across 2 distinct art units, suggesting that the company's technical focus in biotechnology is broad enough to involve different specialized examination groups.
The busiest examiner for the portfolio is SEITZ, ANTHONY JOSEPH, who is responsible for 1 busiest examiner pending action. This single action is part of the 2 pending office actions currently active. With 2 distinct examiners and 2 distinct art units involved, the company must tailor its legal arguments to meet the specific standards of each reviewer. There is no central examiner for the 2 pending office actions, requiring a diversified approach to prosecution. Successfully navigating the requirements of SEITZ, ANTHONY JOSEPH and the other examiner will be critical for the company's progress in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEITZ, ANTHONY JOSEPH | 1 | 68.3% | +27.0% |
| PIHONAK, SARAH | 1 | 61.3% | +42.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18455767 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | PIHONAK, SARAH | 22d |
| 18286966 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | SEITZ, ANTHONY JOSEPH | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18286966 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | SEITZ, ANTHONY JOSEPH | 1629 | Other | Non-Final OA | — | Pending | Oct 13, 2023 |
| 18455767 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | PIHONAK, SARAH | 1627 | §112 | Final Rejection | 22d | Pending | Aug 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial